Skip Navigation

Correction for Daggubati et al., Cardiovasc Res 44 (2) 452-453.
Cardiovascular Research 1997 36(2):246-255; doi:10.1016/S0008-6363(97)00164-8
© 1997 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Corrigendum (v44,p452)
Right arrow Correction (v44,p176)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daggubati, S.
Right arrow Articles by Vesely, D. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daggubati, S.
Right arrow Articles by Vesely, D. L
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators1

Sreedevi Daggubatia,b,*, James R Parksa,b, Rose M Overtona,b, Guillermo Cintrona,b, Douglas D Schockena,b and David L Veselya,b

aDepartments of Medicine, Physiology and Biophysics, James A. Haley Veterans Hospital, 151, 13000 Bruce B. Downs Blvd., Tampa, FL 33612, USA
bUniversity of South Florida Health Sciences Center, Tampa, FL, USA

* Corresponding author. Tel.: +1 813 9727624; Fax: +1 813 9727623.

Objectives: The present investigation was designed to determine the best endogenous plasma marker of early congestive heart failure (CHF). Methods: Forty volunteers with mild CHF (New York Heart Association Class I, n = 12), moderate (Class II, n = 8), or severe (Class III and Class IV, each=n of 5) and 10 age-matched healthy individuals had the simultaneous evaluation of their respective plasma samples by the following radioimmunoassays: atrial natriuretic peptide, ANP; three N-terminal ANP prohormone assays, i.e., proANPs 1–30, 31–67, and 79–98 with the numbers referring to their amino acid (a.a.) sequences in their 126 a.a. prohormone; brain (BNP) and C-natriuretic peptides; N-terminal BNP prohormone; adrenomedullin; neuropeptide Y and endothelin. Results: ProANPs 31–67, 1–30 and 79–98 had 100% (P = 0.01), 83% (P = 0.09) and 50% (P = 0.74) sensitivity in differentiating Class I CHF subjects from healthy subjects. The ANP, BNP, NT-proBNP, CNP, adrenomedullin, neuropeptide Y, and endothelin assays could not differentiate mild CHF subjects from healthy individuals. Logistic regression analysis revealed that only proANP 31–67 significantly (P = 0.0001) discriminated between early CHF (5226±377 pg/ml) and healthy individuals (1595±157 pg/ml). The positive and negative predictive values of proANP 31–67 were excellent (100% for each). The peptides measured in these assays were found to be independent markers of CHF with respect to left ventricular ejection fraction. Conclusions: ProANPs 31–67 is the most sensitive marker in discriminating NYHA Class I CHF subjects from healthy individuals. The ANP, BNP, NT-proBNP, CNP, adrenomedullin, neuropeptide Y and endothelin radioimmunoassays cannot discern mild CHF. These peptides are independent of left ventricular ejection fraction.

KEYWORDS Heart failure; Plasma; Endothelin; Neuropeptide-Y; Adrenomedullin; Humans

1 Presented in part at the American Society of Clinical Investigation Meeting, Washington, DC, April 25–27, 1997.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

Corrigendum to: "Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators" [Cardiovascular Research 36 (1997) 246–255]
Sreedevi Daggubati, James R. Parks, Rose M. Overton, Guillermo Cintron, Douglas D. Schocken, and David L. Vesely
Cardiovasc Res 1999 44: 452-453. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
D. Moertl, R. Berger, J. Struck, A. Gleiss, A. Hammer, N. G. Morgenthaler, A. Bergmann, M. Huelsmann, and R. Pacher
Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1783 - 1790.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. R. Seferian, N. N. Tamm, A. G. Semenov, A. A. Tolstaya, E. V. Koshkina, M. I. Krasnoselsky, A. B. Postnikov, D. V. Serebryanaya, F. S. Apple, M. M. Murakami, et al.
Immunodetection of Glycosylated NT-proBNP Circulating in Human Blood
Clin. Chem., May 1, 2008; 54(5): 866 - 873.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. Latour-Perez, F. J. Coves-Orts, C. Abad-Terrado, V. Abraira, and J. Zamora
Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: A systematic review
Eur J Heart Fail, June 1, 2006; 8(4): 390 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
E. C. Vourvouri, A. F.L. Schinkel, J. R.T.C. Roelandt, F. Boomsma, G. Sianos, M. Bountioukos, F. B. Sozzi, V. Rizzello, J. J. Bax, H. I. Karvounis, et al.
Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device
Eur J Heart Fail, December 1, 2003; 5(6): 767 - 774.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.